secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001104659-25-009906
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics effectuates 1-for-16 reverse stock split effective Feb 7, 2025
--------------------------------------------------------------------------------

- Board approved 1-for-16 reverse split on Jan 29; stockholders approved at Jan 28 special meeting.
- Every 16 shares of common stock reclassified into 1 share; no fractional shares, cash paid for fractions.
- Split-adjusted trading begins Feb 10 under existing symbol BTAI; new CUSIP 09075P204.
- Proportional adjustments to equity plans, stock options, warrants, and other convertible securities.
- Reverse split does not affect authorized shares or par value; shares remain fully paid and non-assessable.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925009906/0001104659-25-009906-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925009906/tm255604d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-009906

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer